Rykindo is a drug owned by Shandong Luye Pharmaceutical Co Ltd. It is protected by 5 US drug patents filed in 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 10, 2032. Details of Rykindo's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9532991 | Risperidone sustained release microsphere composition |
Apr, 2032
(6 years from now) | Active |
| US9446135 | Risperidone sustained release microsphere composition |
Apr, 2032
(6 years from now) | Active |
| US10406161 | Risperidone sustained release microsphere composition |
Apr, 2032
(6 years from now) | Active |
| US10098882 | Risperidone sustained release microsphere composition |
Apr, 2032
(6 years from now) | Active |
| US11110094 | Risperidone sustained release microsphere composition |
Apr, 2032
(6 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Rykindo's patents.
Latest Legal Activities on Rykindo's Patents
Given below is the list of recent legal activities going on the following patents of Rykindo.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 03 Jul, 2024 | US9532991 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 Mar, 2024 | US9446135 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 Mar, 2023 | US10406161 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 Mar, 2022 | US10098882 |
| Patent Issue Date Used in PTA Calculation
Critical | 07 Sep, 2021 | US11110094 |
| Recordation of Patent Grant Mailed
Critical | 07 Sep, 2021 | US11110094 |
| Email Notification
Critical | 19 Aug, 2021 | US11110094 |
| Issue Notification Mailed
Critical | 18 Aug, 2021 | US11110094 |
| Dispatch to FDC | 05 Aug, 2021 | US11110094 |
| Application Is Considered Ready for Issue
Critical | 05 Aug, 2021 | US11110094 |
Several oppositions have been filed on Rykindo's European patents.
EP oppositions
can significantly impact the timeline for the generic launch of drugs. If an opposition results in the
revocation or
amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an
earlier entry
of generic versions into the market. To help you estimate the potential early arrival of Rykindo's generic, the next section provides detailed information on
ongoing and past
EP oppositions related to Rykindo patents.
Rykindo's Oppositions Filed in EPO
Rykindo has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jun 20, 2017, by Lecomte & Partners. This opposition was filed on patent number EP12777430A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP19176691A | Jul, 2021 | Alkermes Pharma Ireland Limited | Opposition rejected |
| EP16179390A | Apr, 2020 | Alkermes Pharma Ireland Limited | Opposition rejected |
| EP16179390A | Apr, 2020 | Aera A/S | Opposition rejected |
| EP12777430A | Jun, 2017 | Lecomte & Partners | Opposition rejected |
US patents provide insights into the exclusivity only within the United States, but
Rykindo is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Rykindo's family patents as well as insights into
ongoing legal events
on those patents.
Rykindo's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Rykindo's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 10, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Rykindo Generic API suppliers:
Risperidone is the generic name for the brand Rykindo. 41 different companies have already filed for the generic of Rykindo, with Dash Pharms having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Rykindo's generic
Alternative Brands for Rykindo
Rykindo which is used for treating schizophrenia in adults., has several other brand drugs using the same active ingredient (Risperidone). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Indivior |
| ||
| Janssen Pharms |
| ||
| Labs Farms Rovi Sa |
| ||
| Teva |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Risperidone, Rykindo's active ingredient. Check the complete list of approved generic manufacturers for Rykindo
About Rykindo
Rykindo is a drug owned by Shandong Luye Pharmaceutical Co Ltd. It is used for treating schizophrenia in adults. Rykindo uses Risperidone as an active ingredient. Rykindo was launched by Shandong Luye in 2023.
Approval Date:
Rykindo was approved by FDA for market use on 13 January, 2023.
Active Ingredient:
Rykindo uses Risperidone as the active ingredient. Check out other Drugs and Companies using Risperidone ingredient
Treatment:
Rykindo is used for treating schizophrenia in adults.
Dosage:
Rykindo is available in for suspension, extended release form for intramuscular use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 37.5MG | FOR SUSPENSION, EXTENDED RELEASE | Prescription | INTRAMUSCULAR |
| 25MG | FOR SUSPENSION, EXTENDED RELEASE | Prescription | INTRAMUSCULAR |
| 12.5MG | FOR SUSPENSION, EXTENDED RELEASE | Discontinued | INTRAMUSCULAR |
| 50MG | FOR SUSPENSION, EXTENDED RELEASE | Prescription | INTRAMUSCULAR |